Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joseph Friddle

Physician Assistant, Medical Greenville, SC Physician Assistant

NPI 1487988838 CMS profile 10472571

2094 Woodruff Rd, Greenville, SC 29607

Open in the dashboard

General payments

$10,373

558 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Friddle of Greenville, SC is reported in the CMS Open Payments database as having received $10,373 across 558 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,076 120
2024 General $2,784 129
2023 General $2,531 125
2022 General $1,556 88
2021 General $1,426 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Friddle
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Joseph Friddle were reported at $2,076. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Joseph Friddle Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,426 $156 $41–$563 $132
2022 $1,556 $185 $55–$649 $149
2023 $2,531 $199 $58–$717 $160
2024 $2,784 $206 $62–$740 $164
2025 $2,076 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,453 104 payments
  2. ITI, Inc. $1,164 54 payments
  3. Otsuka America Pharmaceutical, Inc. $1,155 68 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $714 41 payments
  5. Lundbeck LLC $703 33 payments
  6. Axsome Therapeutics, Inc. $546 26 payments
  7. Tris Pharma Inc $505 23 payments
  8. Corium, Inc. $500 27 payments
  9. Supernus Pharmaceuticals, Inc. $498 13 payments
  10. Alkermes, Inc. $390 18 payments
  11. Other $2,746 151 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,361 557 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. REXULTI Psychiatry $1,145 67 payments
  2. VRAYLAR Neuroscience $1,022 71 payments
  3. CAPLYTA $863 40 payments
  4. TRINTELLIX $714 41 payments
  5. REXULTI Psychiatry $641 30 payments
  6. Auvelity $546 26 payments
  7. Dyanavel XR $505 23 payments
  8. Azstarys $500 27 payments
  9. VRAYLAR Neuroscience $420 32 payments
  10. HETLIOZ $360 16 payments
  11. Other $5,335 264 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

5,226

Median for Physician Assistant: 241

Drug cost

$177,788

Median for Physician Assistant: $4,110

Branded share of claims

20.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Valium Diazepam Brand 12 $22,493
Rexulti Brexpiprazole Brand 13 $18,148
Vraylar Cariprazine Hcl Brand 13 $17,993
Trintellix Vortioxetine Hydrobromide Brand 17 $16,293
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 209 $9,894
Belsomra Suvorexant Brand 17 $7,259
Vyvanse Lisdexamfetamine Dimesylate Brand 18 $7,109
Paxil Paroxetine Hcl Brand 24 $6,813
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 253 $6,113
Lurasidone Hcl Generic 27 $5,328

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$21,435

Medicare's payments for the services billed

Medicare patients

147

Average age 68

Services billed

334

101 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 70%
High blood pressure 60%
Arthritis 60%
Diabetes 27%
Chronic kidney disease 18%
Ischemic heart disease 16%
Osteoporosis 16%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $283
  • Lundbeck LLC $165
$448 13 —
CAPLYTA
  • ITI, Inc. $428
$428 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $351
$351 — —
VRAYLAR
  • AbbVie, Inc. $348
$348 13 —
Dyanavel XR
  • Tris Pharma Inc $178
$178 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

558 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record